

Market Announcement

17 May 2019

LBT Innovations Limited (ASX: LBT) – Trading Halt

Description

The securities of LBT Innovations Limited ('LBT') will be placed in trading halt at the request of LBT, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 21 May 2019 or when the announcement is released to the market.

Issued by

Alex Sutton

Compliance Adviser, Geology, Listings Compliance (Sydney)

17 May 2019

ASX market Announcements

By email: tradinghaltssydney@asx.com.au

Dear Sir/Madam

**TRADING HALT REQUEST
LBT INNOVATIONS LIMITED (ASX: LBT)**

LBT Innovations Limited (**LBT** or the **Company**) requests a trading halt be placed on its securities immediately, pending an announcement to the market in relation to the results of its submission to the US Food & Drug Administration (**FDA**). Further detail in relation to the FDA submission can be found in the Company's announcement to the ASX on 21 December 2018.

LBT is not aware of any reason that a trading halt should not be placed on its securities.

The trading halt is expected to be lifted by no later than commencement of trading on 21 May 2019, pending release of an announcement by the Company in relation to its submission to the FDA.

Yours sincerely,



Dan Hill

Company Secretary

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. The APAS® instrument is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

CONTACTS

LBT Innovations	Investor Enquiries
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com